Anterix Inc. is leveraging its 900 MHz radio spectrum to build private broadband networks for utility and critical infrastructure clients, aiming for long-term growth through new products and satellite connectivity. The company enjoys strong institutional support, with 87.7% ownership, reflecting confidence in its strategy. Analysts have maintained a consistent price target of $69, signaling stable market outlook and investor trust in Anterix's business direction.
Jumia Technologies AG, a leading African e-commerce platform, currently shows a highly negative Return on Invested Capital (ROIC) of -256.50%, reflecting its aggressive growth and market expansion strategy. This negative ROIC, compared to its Weighte...
Inventiva, a clinical-stage biopharmaceutical company, announced the total number of shares and voting rights as of May 22, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights, both gross and net. This disclosure...
Inventiva, a biopharmaceutical company, announced the details for its Annual General Meeting (AGM) on June 30, 2026, where shareholders will vote on a key resolution involving a master agreement with the European Investment Bank (EIB). This agreement...
Inventiva, a clinical-stage biopharmaceutical company, announced the total number of shares and voting rights as of May 22, 2026. The company reported 209,007,475 shares outstanding with 218,082,368 total voting rights, both gross and net. This discl...
Inventiva announced the availability of documents for its Combined General Meeting on June 30, 2026, where shareholders will vote on key resolutions including the repayment of loans to the European Investment Bank (EIB) and the buyback and cancellati...
